Business Description
Inhibikase Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45719W2052
Share Class Description:
STU:IQT0: Ordinary SharesTotal Employee Number:
35Description
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4483.4 | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.8 | |||||
3-Year EPS without NRI Growth Rate | 51 | |||||
3-Year FCF Growth Rate | 59 | |||||
3-Year Book Growth Rate | -36 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 30.14 | |||||
Quick Ratio | 30.14 | |||||
Cash Ratio | 29.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -215.2 | |||||
Shareholder Yield % | -0.84 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -43.99 | |||||
ROA % | -41.28 | |||||
ROIC % | -1134.61 | |||||
3-Year ROIIC % | -563.5 | |||||
ROC (Joel Greenblatt) % | -51507.69 | |||||
ROCE % | -48.17 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.66 | |||||
Price-to-Tangible-Book | 1.66 | |||||
EV-to-EBIT | -4.37 | |||||
EV-to-EBITDA | -4.37 | |||||
EV-to-Forward-Revenue | 1358.04 | |||||
EV-to-FCF | -6.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.68 | |||||
| Price-to-Net-Cash | 1.69 | |||||
Earnings Yield (Greenblatt) % | -22.88 | |||||
FCF Yield % | -10.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibikase Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.369 | ||
| Beta | 0.0346 | ||
| 3-Year Sharpe Ratio | -34.93 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.27 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.27 - 3.27 | ||
| Shares Outstanding (Mil) | 157.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibikase Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibikase Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 117 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:50 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 26 days | ||
| General meeting for 2026 | 2026-06-26 16:00 | 3.27 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.27 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 3.27 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 3.27 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 3.27 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 3.27 (+0.00%) | ||
| General meeting for 2025 | 2025-06-27 16:00 | 3.27 (+0.00%) |
Show
Entries
Inhibikase Therapeutics Inc Frequently Asked Questions
What is Inhibikase Therapeutics Inc(STU:IQT0)'s stock price today?
The current price of STU:IQT0 is €3.27. The 52 week high of STU:IQT0 is €3.27 and 52 week low is €3.27.
When is next earnings date of Inhibikase Therapeutics Inc(STU:IQT0)?
The next earnings date of Inhibikase Therapeutics Inc(STU:IQT0) is 2026-08-14 Est..
Does Inhibikase Therapeutics Inc(STU:IQT0) pay dividends? If so, how much?
Inhibikase Therapeutics Inc(STU:IQT0) does not pay dividend.
Press Release
Articles on Inhibikase Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers